ArticleDigestive diseases and sciences2026
Histopathologic Characteristics in Per-oral Endoscopic Myotomy Biopsy Among Achalasia Subtypes.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAchalasia is an esophageal motility disorder categorized into three subtypes based on esophageal motility patterns assessed by high-resolution manometry (HRM). This study aimed to evaluate and compare the histopathological characteristics of the muscularis propria at the lower esophageal sphincter (LES) and the esophageal body among different achalasia subtypes.
methodsA total of 26 patients initially diagnosed with achalasia and undergoing peroral endoscopic myotomy (POEM) between May 2021 and November 2022 were prospectively enrolled. During POEM, biopsy specimens of the muscularis propria were obtained from the LES and the distal esophagus (approximately 5 cm above the LES). Tissue sections were stained with hematoxylin and eosin (H&E) and Masson's trichrome, and immunohistochemical staining was performed for CD117, S100, CD3, CD20, CD4, and CD8. Control samples of histologically normal LES tissue were obtained from five patients undergoing surgery for gastric malignancy.
resultsOf the 26 patients, 14 (53.8%) were classified as type I and 12 (46.2%) as type II achalasia. The esophageal diameter was significantly larger in type I than in type II achalasia (4.57 ± 1.09 cm vs. 3.25 ± 0.88 cm, p = 0.005). At the LES, the degree of fibrosis and the proportion of severe ganglion loss in the muscularis propria were significantly higher in type I achalasia than in controls (p < 0.05). The number of interstitial cells of Cajal (ICCs) was significantly lower in type I achalasia compared to controls (p = 0.031). Although a difference was observed in CD4 + T cell counts among type I, type II, and control groups (p = 0.045), post-hoc pairwise comparisons did not reveal significant differences. No significant differences were observed in the distal esophagus and the LES regarding inflammation, fibrosis, ganglion loss, ICC density, or counts of CD3 + , CD4 + , CD8 + , or CD20 + cells (p > 0.05). Mild fibrosis was more frequently observed in the distal esophagus than in the LES, but this difference was not statistically significant (p > 0.05).
conclusionCompared to controls, type I achalasia is associated with significantly greater fibrosis, more severe ganglion loss, and a reduced number of ICCs in the muscularis propria at the LES. These findings suggest that type I achalasia may represent an advanced stage of the disease, characterized by inflammation-driven ganglion degeneration, loss of ICCs, and progressive fibrosis.
Indexed as
Identifiers
41039163What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.